Synbio International Achieves DWAC and DRS Eligibility to Enhance Trading Efficiency

Synbio International Inc. (OTC: SYIN) announced that the company has been approved for Deposit/Withdrawal at Custodian (DWAC) and Direct Registration System (DRS) processing through its transfer agent, Pacific Stock Transfer Company. This milestone represents an important step in Synbio's ongoing efforts to modernize its trading infrastructure and improve accessibility for both existing shareholders and prospective investors. DWAC eligibility enables electronic transfer of shares between broker-dealers and the company's transfer agent, eliminating the need for physical share certificates, reducing settlement times, and lowering transaction friction for more efficient trading in the open market.

In parallel, DRS allows shareholders to hold their shares directly on the books of the company in electronic form, without requiring a physical certificate or intermediary custody. This provides investors with greater control, enhanced ownership security, and simplified transferability. Claudio Solitario, CEO of Synbio International, stated that achieving DWAC and DRS eligibility is a foundational step in strengthening Synbio's capital markets platform. As the company continues to advance strategic initiatives, including planned financing activities and partnership developments, it is critical that the stock is easily accessible and efficiently tradable for the investment community.

This development positions the company to move quickly as it executes on a number of near-term initiatives currently in progress. The transition toward a more investor-ready, execution-focused public company platform comes with multiple near-term capital markets and operational catalysts expected. The company's focus on clinically validated AI-driven medical diagnostics through strategic partnerships and research collaborations aims to bridge the gap between wellness and medicine. More information about the company's initiatives can be found at https://www.synbiointl.com.

The modernization of trading structure through DWAC and DRS eligibility enables faster trading and broader market access for Synbio International. This infrastructure improvement reduces barriers for investors seeking exposure to the company's medical research and technology developments. The electronic processing capabilities eliminate physical certificate handling, which historically created delays and administrative burdens in share transactions. For current shareholders, the direct registration system offers enhanced security and control over their investments without relying on intermediary custodians.

This announcement comes as Synbio International continues to develop science-based solutions that improve quality of life and empower healthcare providers. The trading infrastructure enhancements support the company's growth trajectory and facilitate more efficient capital market interactions. The combination of DWAC and DRS processing creates a streamlined environment for share transfers, benefiting both institutional and individual investors participating in the company's public market presence. These developments align with broader industry trends toward digital securities processing and increased market accessibility for emerging technology companies.